Here is another good news/bad news column about the 112th Congress.

With fakes of the cancer drug Avastin popping up in U.S. clinics in the past few months, patients are naturally worried about whether their medicines are safe.  Considering eighty percent of the ingredients in U.S. medicines come from overseas – mostly from China and India because their products are generally...

Nobody has asked what financial and scientific burdens new legislation will place on the Food and Drug Administration.

Until government price controls are lifted, the makers of generics will be unable to cover their production costs.

We should increase the availability of safe and effective generic drugs and provide a framework for people to make wider use of them.

Every day patients receive treatments that do not work properly. For many this means no relief from symptoms, but for some death is the result. Yet concerted action against such products is limited. Before we can discuss why that's the case, I will attempt to explain what kind of products don’t work, and what we should call them.

New data show that health spending over the past several years has been normalizing toward the rate of general inflation, rather than growing higher and higher, as had been the case almost continuously since the 1970s.

With 100,000 patients dying every year from dangerous medicines, it is time to take concrete actions. Establishing a treaty against fake medicines should be the first step.